

INTERIM REPORT

January to March 2009



 **VITA 34**

CONSOLIDATED KEY FIGURES

		01/01- 03/31/2009	01/01- 03/31/2008
STEM CELL PREPARATIONS			
Umbilical cord blood storages	Number	2,448	2,453
PROFIT / LOSS			
Revenues	EUR k	3,402	3,582
Gross profit	EUR k	2,270	2,385
EBIT	EUR k	-195	-345
Period result	EUR k	-84	88
		03/31/2009	03/31/2008
BALANCE SHEET / CASH FLOW			
Total assets	EUR k	29,134	31,177
Equity	EUR k	18,040	19,826
Equity ratio	%	61.9	63.6
Liquid funds including other financial assets	EUR k	5,728	8,894
Capital expenditures*	EUR k	71	236
Depreciation*	EUR k	130	101
Cash flow from operating activities	EUR k	-1,501	-1,748
EMPLOYEES			
Employees (as of March 31)	Number	102	112
Personnel expenditures	EUR k	1,268	1,433

*Information for tangible and intangible assets

CONTENTS

	PAGE
LETTER TO THE SHAREHOLDERS	4
GROUP INTERIM REPORT	6
1 Summary	6
2 Revenue and Profit Situation	6
3 Financial and Asset Situation	7
4 Investments	9
5 Employees	9
6 VITA 34 on the Capital Market	9
7 Risks and Market Opportunities	10
8 Outlook	11
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	12
1 Condensed Consolidated Income Statement	12
2 Condensed Consolidated Balance Sheet	13
3 Condensed Consolidated Statement of Cash Flows	15
4 Condensed Consolidated Statement of Changes in Equity	16
NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS	17
FINANCIAL CALENDAR AND CONTACT	20

LETTER TO THE SHAREHOLDERS

Dear Shareholders and Friends of VITA 34,

The first quarter of 2009 developed in accordance with our plans. In an environment that is dominated by bad economic news on a daily basis, we can be satisfied with this development. However, even in our case there was a slight decrease in revenues and storages in Q1, as we had already anticipated at the end of last year. We can evaluate the development of business of the coming months with a high degree of accuracy based on the inquiries and information requests received. Q1 corresponded with this outlook. We have clearly been seeing more inquiries again since the beginning of the year, which has us thinking positively. For example, in Q1 2009 there were 33 percent more interested parties than in Q4 2008. This does not mean that we will see a corresponding percental growth in the coming months, however, it does allow us to expect increasing revenues.

Yet, let us first take a look at the Q1 numbers. Revenues were, as expected, EUR 3.4 million, which is equivalent to a decline of 7.1 percent to the first quarter of 2008. Here, we stored 2,448 preparations, roughly the same amount as in Q1 of the previous year when the figure was 2,453 preparations. The fact that there was a decrease in revenues nonetheless, is due to a change in revenue distribution. The storages for our Spanish cooperation partner Secuvita increased, whereas the number of storages in Germany decreased. This shift did indeed cause a slight decrease in revenues, however, this was not to the detriment of our profits, as the EBIT or earnings before interest and taxes show. Whereas we posted a loss of EUR -0.3 million in the previous year's quarter, we improved this to EUR -0.2 million in Q1 2009. Thus, we are in accordance with

the plan of achieving a black zero for the entire year with regard to EBIT (prior year: EBIT EUR -2.4 million).

Apart from this encouraging perspective, VITA 34 also continued to improve strategically. For instance, we entered into a cooperative agreement with the Slovenian company Izvorna celica. Slovenia opens up an additional country for VITA 34, similar to the cooperation with the Spanish company Secuvita. In the meantime, all permits have been issued by the responsible authorities, so that the first storages from Slovenia can take place in Q2 already.

With Slovenia we are active in an additional market that matches our growth criteria exactly. There is a sufficiently high level of willingness to make private expenditures for health care, the regulatory prerequisites exist and there is very little competitive pressure. All of these are prerequisites for achieving positive results in the short to medium term in the respective countries.

Our expansion abroad, however, is not finished with the cooperative agreements entered into. In the medium term we plan on opening up additional markets. Here, apart from our more than eleven years of expertise and the "Made in Germany" quality, we are also helped by the increasing acceptance for the storage of umbilical cord blood. Thus, in Q1 2009 we saw the press report more positively on the topic of stem cells from umbilical cord blood, which was noticeable in the increases in inquiries we received.



The increasing acceptance is also expressed by the cooperative agreements entered into with health insurance companies. In Q1 alone we were able to close seven additional agreements, so that we now cooperate with 37 public health insurance companies as well as with Debeka, the largest private health insurer. This shows that there is an increasing demand for our services arising from the cooperation with a certain time lag.

Last but not least, the increasing uses for stem cells from umbilical cord blood are leading to a continuously more positive public perception. One example of this is also our cooperation with the Technical University Munich on the clinical testing of stem cells from umbilical cord blood in newly manifested Type 1 diabetes. This clinical study is being conducted in parallel with a pilot study in the USA. The goal here is to protect and regenerate respectively the bodies own insulin producing cells at the start of the disease. As a result, the risks for the eyes, kidneys and blood vessels that still exist could be eliminated for these patients in the future. At the end of Q1 we transferred the first preparation from VITA 34 to Munich for transplantation.

We expect an additional moderate increase in revenues altogether for 2009 and 2010. In addition, our declared goal for 2009 is to achieve an EBIT with a black zero. With the numbers from Q1 and the strategic course set, we see ourselves as being on track here. The increasingly positive perception amongst the public for the use of umbilical cord blood also bolsters our belief in an increasingly dynamic development in this field of health care. Moreover, the high acceptance of our newer products VITAplusSpende as well as Vita 34 max shows that we are on the right course. We would welcome it, if you would accompany us on the path in the future, as well. Even if the share price development in Q1 was negative given the market environment, we are convinced that a positive development of the business is the best prerequisite for a resumption of persistently higher share prices.

Leipzig, April 15, 2009

Dr. Eberhard Lampeter

Peter Boehnert

GROUP INTERIM REPORT

01/01 to 03/31/2009

1 SUMMARY

VITA 34 is the leading umbilical cord blood bank in the German speaking countries and one of the leading umbilical cord blood banks in Europe. The VITA 34 market share of storages of umbilical cord blood transplants in Germany is, conservatively estimated, some 66 percent. The company offers expecting parents a provisionary service for their newborn child. The blood taken from the umbilical cord immediately after birth contains valuable stem cells, the youngest adult stem cells there are, which can be used later in the therapy of severe diseases and in regenerative medicine. The stem cells are prepared by VITA 34 in the Glass Laboratory in Leipzig, and they are stored in the gaseous phase of liquid nitrogen at approx. negative 196 degree Celsius until a possible use.

The VITA 34 services are offered in different variants, which are associated with different pricing models. For example, there has been a variant since the end of Q3 2008, in which the umbilical cord blood storage is combined with a genetic test of the blood for detecting different diseases. VITA 34 is addressing the differing needs of varying customer groups through product differentiation.

The development of VITA 34's business overall is determined by the extent to which the target group of expecting parents agree that the storage of umbilical cord blood transplants makes sense, and the extent to which they have the financial means to expend for this. VITA 34 endeavors to increase the acceptance of the private storage of umbilical cord blood transplants in Germany through targeted information. In Germany, the rate based on all births is some 2 percent, in Asian states up to 15 percent is achieved. Due to the noticeable darkening of the economy in Germany, there should be a reduction in private consumption, as well.

Nonetheless, VITA 34 is confident that growth can be realized with its services, even in the changing environment.


VITA 34 is increasingly using its expertise as the oldest and most experienced private European umbilical cord blood bank abroad. Legislation in several European countries has been adapted to EU requirements. Thus, the market entry conditions for the service provider have improved.

2 REVENUE AND PROFIT SITUATION

In Q1 2009, VITA 34 was able to parallel the level of the corresponding period of the prior year with storages of 2,448 preparations as compared with 2,453 preparations. Thus, total number of stem cell preparations stored at VITA 34 totaled some 60,000 as of March 31, 2009.

Revenues in Q1 2009 were EUR 3.4 million as compared with EUR 3.6 million in Q1 of the previous year. The slight reduction in revenues can be attributed to a change in revenue distribution. The number of storages for our Spanish cooperation partner Secuvita increased, and these are associated with a lower revenue and lower gross margin, however, they have a higher EBIT. In contrast, the number of storages in Germany declined.

The gross profit from revenues decreased slightly from EUR 2.4 million in the prior year to EUR 2.3 million in Q1 2009. Other operating income, on the other hand, rose from EUR 0.2 million to EUR 0.3 million.



Expenditures for marketing and sales dropped to EUR 2.1 million, following EUR 2.3 million in the prior year's period.

The costs for administration and business development listed as administrative expenses were lower, as planned, in the wake of the optimization measures initiated. It was EUR 0.6 million, following EUR 0.7 million the previous year.

The profit/loss before interest and taxes, EBIT, improved slightly to EUR -0.2 million. In the corresponding prior year's quarter the EBIT was EUR -0.3 million. The financial profit/loss was nearly neutral at EUR -9,000, following a positive total of EUR 95,000 the prior year.

The net profit/loss from continued operations in accordance with IFRS improved from EUR -0.2 million the prior year to EUR -0.1 million. This corresponds with the period profit/loss for Q1 2009. In the prior year there was still a profit of EUR 0.3 million from a discontinued business segment, the activities in the USA. Thus, the period profit/loss for Q1 2008 was a total of EUR 0.1 million.

3 FINANCIAL AND ASSET SITUATION

Financial Situation

The cash of VITA 34 International AG as of March 31, 2009 was EUR 4.7 million, and was reduced in Q1 2009 by some EUR 2.5 million, among other things by investing EUR 1 million as term deposits (other financial assets). The cash as of March 31st was comprised of cash and cash equivalents in the amount of EUR 3.8 million and current financial investments of some EUR 0.9 million.

As planned, the cash flow of the company in Q1 2009 was negative. The cash flow from operating activities was EUR -1.5 million. This can be primarily attributed to the reduction in liabilities. The cash flow from investing activities was negative EUR -1 million due to the investment of term deposits. There was no change in cash flow due to financing activities.

Assets

VITA 34 International AG has a solid balance sheet structure. As of March 31, 2009, the equity ratio was 62 percent and had increased slightly as compared to the status at the end of 2008 when it was 60 percent. The balance sheet total decreased slightly to EUR 29.1 million as of March 31, as compared to EUR 30.3 million at the end of 2008.

Non-current assets of EUR 19.8 million continued to represent the majority of the assets. As compared to December 31, 2008, this figure changed only marginally. The largest item within the non-current assets is the goodwill of VITA 34 AG, which remained unchanged and is listed in the VITA 34 International AG balance sheet at EUR 11.9 million. This is followed by the tangible assets, whose value dropped slightly from EUR 3.1 million at the end of 2008 to EUR 3.0 at the end of Q1 2009. The non-current receivables, resulting from partial payment models decreased slightly from EUR 2.0 million as of year's end 2008 to EUR 1.9 million.

38 health insurance companies work together with VITA 34 as cooperation partners.


The current assets decreased from EUR 10.6 million at the end of 2008 to EUR 9.4 million as of March 31, 2009. This can mainly be attributed to the reduction of cash and cash equivalents, which decreased from EUR 6.4 million to EUR 3.8 million. Receivables on the other hand rose to EUR 1.9 million following EUR 1.6 million at year's end 2008.

On the liabilities side of the balance sheet, the equity as of the end of March 2009 was some EUR 18.0 million as compared with EUR 18.1 million as of year's end 2008. The registered capital remained constant at EUR 2.6 million.

The non-current liabilities and deferred income were nearly unchanged at EUR 8.6 million. As in the past, the

largest item here was deferred income totaling EUR 5.4 million. This is where the storage fees for the stem cell preparations paid by customers in advance are contained. The storage fees are dissolved linearly over the prepaid term.

The current liabilities and deferred income decreased significantly by EUR 1.1 million from EUR 3.6 million at the end of 2008 to EUR 2.5 million as of March 31, 2009. Here, the liabilities were significantly reduced from EUR 1.1 million at the end of 2008 to EUR 0.3 million at the end of Q1 2009.



¹ Including Other financial assets

² Excluding Deferred income



4 INVESTMENTS

VITA 34 made investments in plant and material and intangible assets in the amount of EUR 0.1 million in Q1 2009. As compared with the prior year's period, the investments were below those of the prior year, in which EUR 0.2 million were spent. The investments in the reported period were mainly in expanding the cryo and storage capacities at the company's headquarters in Leipzig. Moreover, in the IT area, VITA 34 acquired and installed additional process software. It is expected that there will be no significant change in investment activity in the coming quarter.

5 EMPLOYEES

As of March 31, 2009 VITA 34 employed 102 people in the group (without trainees and temporary workers). As a result of headcount adjustments, this meant a reduction of the number of employees by nine as compared to year's end 2008.


At the end of Q1 there were 22 employees in the Commercial department, 43 in Production and Quality Assurance, and 37 employees in Marketing and Sales. Based on an internal restructuring 10 persons from the Marketing and Sales department were assigned to Production and Quality Assurance.

6 VITA 34 ON THE CAPITAL MARKET

Following a weak year for the stock markets in 2008 they initially continued to be under pressure in Q1 2009. In the wake of disappointing economic news, the share prices on international markets and the German stock market decreased again significantly, especially in February and at the beginning of March. The German DAX index lost a total of 15 percent of its value from year's end 2008 until March 31, 2009. The SDAX, an indicator for second-line stocks, showed declines of a similar magnitude of nearly 15 percent in Q1 2009.

The VITA 34 share price developed in accordance with the trend of the overall market in the first quarter. Subsequent to a year-end closing price of EUR 3.00 the share climbed to EUR 3.30 on January 6, thus reaching its highest recorded price for the quarter. Due to the general malaise in the markets, the VITA share price was also subject to a decline. The share price reached its low of EUR 2.11 on March 16th. Ultimately, there was a recovery up to EUR 2.50 at the end of March. In all, VITA lost nearly 17 percent of its valuation in the first quarter. Although this development can be traced to the environment, the Management Board considers this price development to be unsatisfactory.

The average trading volume in Q1 2009 was roughly at the level of the previous year. Per day an average of 2,526 shares were traded in the first three months. With a share of some 92 percent, the XETRA was the most liquid exchange. In order to ensure good liquidity with tight margins between two-way prices on the Xetra, a designated sponsor was active on behalf of VITA 34, ICF Kursmakler AG.



VITA 34 is listed in the Prime Standard segment, the quality segment, of Deutsche Börse AG. The company continued to communicate with the financial media, Analysts and investors in a timely, transparent and intensive manner in Q1 2009. Accordingly, the financial journalists and institutional investors were shown the business model and outlook for VITA 34 in personal discussions. VITA 34 plans on keeping the capital market communication at a high level, and will present itself at several capital market conferences in the upcoming months.

The purchases of their own company's shares show how convinced the Management Board is regarding the future outlook for the company. Accordingly, Management Board Chairman of VITA 34 International AG, Dr. med. Eberhard Lampeter bought more than 23,000 VITA shares in the middle of March 2009. The shares were from an institutional investor, whose portfolio was liquidated.

The annual report for 2008 was already published on February 27, and it can be downloaded from the Investor Relations section of the company website. Additional information is also available for download there. VITA 34 is always available for investor questions via email at ir@vita34.de.

7 RISKS AND MARKET OPPORTUNITIES

The risks and market opportunities for VITA 34 have not changed significantly from those contained in the 2008 Annual Report.

INFORMATION AND KEY FIGURES ON THE SHARES

Ticker symbol / Reuters symbol	V3V / V3VGn.DE
Securities number / ISIN	A0BL84 / DE000A0BL849
Initial quotation	03/27/2007
Market segment	Prime Standard
Index	CDAX, Prime All Share, Technology All Share, Prime IG Biotechnology
Opening / High / Low / Closing price 1st quarter 2009 (Xetra)	3.00 EUR / 3.30 EUR / 2.11 EUR / 2.50 EUR
Number of shares issued	2,646,500
Freefloat as of 03/31/2009	49.2%
Market capitalization as of 03/31/2009	6.6 Mio. EUR
Designated Sponsor	ICF Kursmakler AG

The number of treatments for severe diseases with precautionarily stored umbilical cord stem cells increased by 64 percent in 2008.

8 OUTLOOK

VITA 34 expects overall a moderate growth in revenues for 2009 and 2010 considering the general economic situation. Thanks to the process and cost optimizations initiated, an EBIT with a black zero is expected for 2009. VITA 34 considers itself to be on course with the development of business in Q1. The requests for information increased significantly by some 33 percent in the first months of the year, which means that increasing revenues can be expected in the coming months. In addition, an improvement in EBIT was achieved in Q1 despite the expected decline in revenues. This shows that the cost basis has dropped in the mean time, such that attainment of break-even is plausible on an annual basis with resumed growth in revenues.

The important cooperative research efforts with regard to Diabetes Type 1 and early childhood brain damage are experiencing a clear media response. So for example, the first therapeutic tests with umbilical cord blood stored with VITA 34 in each case have been reported on numerous times in the trade and general press. This helps the effort of getting our offering in front of the public and should be noticeable in the medium term in an increasing interest for the storage of umbilical cord blood.

The cooperation agreements entered into with the Slovenian company Izvorna celica should lead to the first storages at VITA 34 in Q2 2009. Slovenia has some 20,000 births annually.

Since the fall of 2008 VITA 34 also offers testing of the umbilical cord blood for genetic susceptibilities. This offer has been well accepted by parents, such that VITA 34 is continually testing additional products as an extension of the existing offerings.

In the coming months, VITA 34 also plans on concluding additional cooperative agreements with the health insurance companies. At the end of Q1 there were already 37 agreements with public health insurance companies as well as with Debeka. A positive effect on the development of business with a time lag can be expected from the cooperation.

With the existing liquidity and based on the development of business that is taking shape, VITA 34 sees itself well positioned to achieve the goals set.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

03/31/2009

1 CONDENSED CONSOLIDATED INCOME STATEMENT

EUR K	NOTE	01/01- 03/31/2009	01/01- 03/31/2008
Continuing operations			
Revenues		3,402	3,582
Cost of sales		-1,132	-1,197
Gross profit		2,270	2,385
Other operating income		261	226
Selling expenses		-2,118	-2,285
Administrative expenses		-553	-652
Other operating expenses		-55	-19
Net operating income		-195	-345
Finance revenues		43	140
Finance costs		-52	-45
Earnings before taxes		-204	-250
Income tax income	4	120	90
Profit from continuing operations		-84	-160
Discontinued operation			
Profit / Loss from discontinued operations		0	248
Period result		-84	88
Earnings per share, basic / diluted (EUR)		-0.03	0.03
Earnings per share from continuing operations, basic / diluted (EUR)		-0.03	-0.06

2 CONDENSED CONSOLIDATED BALANCE SHEET (ASSETS)

EUR K	NOTE	03/31/2009	12/31/2008
Non-current assets			
Goodwill		11,911	11,911
Intangible assets		887	930
Property, plant and equipment		3,033	3,054
Investments		26	26
Other financial assets		35	35
Deferred tax assets		859	736
Non-current trade receivables		1,945	1,996
Restricted Cash		1,068	1,068
		19,764	19,756
Current assets			
Inventories		562	584
Trade receivables		1,929	1,600
Other receivables and assets		1,151	1,118
Short-term investments		897	876
Other financial assets		1,000	0
Cash and cash equivalents	3	3,831	6,374
		9,370	10,552
		29,134	30,308

2 CONDENSED CONSOLIDATED BALANCE SHEET (LIABILITIES)

EUR K	NOTE	03/31/2009	12/31/2008
Equity			
Issued capital		2,647	2,647
Capital reserves		23,211	23,192
Revenue reserves		-7,818	-7,734
		18,040	18,105
Non-current liabilities and deferred income			
Interest-bearing loans		1,500	1,500
Silent partners' interests		940	940
Deferred grants		735	741
Deferred income		5,443	5,405
		8,618	8,586
Current liabilities and deferred income			
Trade payables		317	1,087
Silent partners' interests		503	497
Provisions		2	105
Income tax liabilities		208	208
Interest-bearing loans		125	125
Deferred grants		70	81
Other liabilities		715	993
Deferred income		536	521
		2,476	3,617
		29,134	30,308

3 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EUR K	NOTE	01/01- 03/31/2009	01/01- 03/31/2008
Cash flow from operating activities			
Earnings before taxes		-204	-250
Adjusted for:			
Amortization and depreciation		130	101
Profit / loss from disposal of non-current assets		5	0
Other non-cash expenses and income		97	-2
Exchange differences		-7	-15
Finance revenues		-43	-140
Finance expenses		52	45
Expenses of stock-based compensation		19	19
Cash flow from ordinary operations:			
+/- Trade receivables and other receivables and assets		-311	-825
+/- Inventories		22	70
+/- Trade payables and other liabilities		-1,162	-787
+/- Provisions		-103	-133
+/- Deferred income		53	89
Interest paid		-46	-45
Income taxes paid		-3	0
Cash flow from operating activities		-1,501	-1,873
Cash flow from investing activities			
Purchase of intangible assets		-25	-25
Purchase of property, plant and equipment		-46	-211
Purchase of short-term financial asset		-1,000	0
Interest received		22	125
Cash flow from investing activities		-1,049	-111
Cash flow from financing activities			
Changes in silent partnerships		0	6
Loan redemption		0	-88
Cash flow from financing activities		0	-82
Net change in cash and cash equivalents from continued operations		-2,550	-2,066
Net change in cash and cash equivalents		-2,550	-2,066
Cash and cash equivalents at the beginning of the reporting period		6,374	9,002
Net foreign exchange difference		7	-8
Cash and cash equivalents at the end of the reporting period	3	3,831	6,928
Short-term investments		897	1,966
Liquid funds		4,728	8,894

4 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

EUR K	ISSUED CAPITAL	CAPITAL RESERVE	REVENUE RE- SERVES	OTHER RE- SERVES	TOTAL EQUITY
January 1, 2008	2.647	23.116	-6.022	-12	19.729
Book profits / (losses) recorded in equity				13	13
Difference arising from foreign currency translation				-23	-23
Stock-based compensation		19			19
Period result			88		88
Total period result	0	19	88	-10	97
March 31, 2008	2.647	23.135	-5.934	-22	19.826
January 1, 2009	2.647	23.192	-7.734	0	18.105
Stock-based compensation		19			19
Period result			-84		-84
Total period result		19	-84		-65
March 31, 2009	2,647	23,211	-7,818	0	18,040

NOTES ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1 COMPANY INFORMATION

The parent company VITA 34 International AG (the "Company") headquartered in Leipzig (Germany), Deutscher Platz 5 a, registered under HRB 20339 in the Commercial Register of the Leipzig District Court, is purely a holding company, which has a management and financing function for its subsidiary companies. Its subsidiary companies (referred to along with the Company as "Group") are active in the field of umbilical cord blood storage. The purpose of the company is the collection, preparation and storage of stem cells from umbilical cord blood, as well as the development of cell therapy processes.

The unaudited, condensed, consolidated interim financial statements for the period from January 1 until March 31, 2009 were approved for publication by the Management Board on April 14, 2009.

2 ACCOUNTING AND VALUATION PRINCIPLES

2.1 Basis for the Preparation of the Financial Statements

The preparation of the group interim financial statements for the period from January 1 until March 31, 2009 has been conducted in accordance with IAS 34 "Interim Financial Reporting."

The group interim financial statements do not contain all of the explanations and information prescribed for the annual financial statements and should be read in conjunction with the group financial statements as of December 31, 2008.

2.2 Significant Accounting and Valuation Methods

The accounting and valuation methods used to prepare the group interim financial statements correspond with the methods used in the preparation of the group financial statements for the fiscal year as of December 31, 2008.

The group used the following new and revised IFRS standards and interpretations for the first time as of January 1, 2009:

- :: Amendments to IFRS 1 and IAS 27: Acquisition Costs for a Participation in a Subsidiary Company, Jointly Managed Companies or Associated Companies
- :: Amendments to IFRS 2: Share-Based Compensation
- :: Amendments to IAS 1: Presentation of the Financial Statements
- :: Amendments to IAS 23: Debt Capital Costs
- :: Amendments to IAS 32 and IAS 1: Puttable instruments and obligations arising on liquidation
- :: IFRIC 13: Customer Loyalty Programs
- :: IFRIC 14: The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction
- :: Improvements to IFRS 2008

The standards and interpretations required to be used for the first time starting January 1, 2009 resulted in no significant effects on the interim financial statements of VITA 34 International AG.

3 CASH AND CASH EQUIVALENTS

For the purposes of the consolidated statement of cash flows, the cash and cash equivalents consist of the following:

CASH AND CASH EQUIVALENTS	03/31/2009	03/31/2008
	EUR K	EUR K
Cash at banks and in hand	3,831	6,928
	3,831	6,928

4 INCOME TAXES

The significant components of the income tax expenditures listed in the condensed consolidated income statement consist of the following:

MAJOR COMPONENTS OF THE INCOME TAX INCOME / EXPENSE	01/01-03/31/2009	01/01-03/31/2008
	EUR K	EUR K
Current income tax		
Current income tax expense	3	0
Deferred income tax		
Origination and reversal of temporary differences	-7	29
On unused tax losses	-116	-119
Income tax income	-120	-90

5 SEGMENT REPORTING

The company currently has only one business segment subject to reporting, since the group is exclusively involved in the storage of umbilical cord blood.

5.1 Information Concerning Geographic Regions

The company earns its income exclusively in Europe. Here, in the period from January 1 to March 31, 2009 income of EUR 2,872 k (January 1 to March 31, 2008: EUR 2,916 k) was earned in the geographic region of Germany, Austria and Switzerland, and in the Spain region income of EUR 530 k (January 1 to March 31, 2008: EUR 666 k) was earned.

The income was assigned to the geographic regions, taking the revenues achieved in the respective countries into consideration.

5.2 Information Concerning Important Customers

Income with a single external customer is listed under group income, which exceeds 10% of the income of the group. Income in the period from January 1 to March 31, 2009 was EUR 530 k (January 1 to March 31, 2008: EUR 666 k).

6 INFORMATION ON RELATIONSHIPS TO FRIENDS AND FAMILY

The following table contains the total amounts arising from transaction between friends and family in the period from January 1 to March 31, 2009 and 2008:

EXPENSES TO RELATED PARTIES	TOTAL AMOUNT OF TRANSACTIONS	
PERIOD FROM 01/01 – 03/31	2009	2008
	EUR K	EUR K
A member of the Supervisory Board is Chairman of the U.S. law offices Dillworth Paxon. Law services were purchased from Dillworth Paxon for the following amounts:	0	4
Compensation of key management personnel of the Group:		
Short-term benefits::		
- Remuneration of the Supervisory Board	15	15
- Management Board salaries	197	132
Other long-term benefits:		
- The Management Board of VITA 34 AG	0	24
Share-based compensation		
- The Managements Board of VITA 34 AG	19	19

FINANCIAL CALENDAR 2009

2009

April 15, 2009	Publication of Q1 Report
July 14, 2009	Publication of Q2 Report
July 15, 2009	Annual General Meeting
October 14, 2009	Publication of Q3 Report
November 2009	Analysts' conference

CONTACT

Peter Boehnert
VITA 34 International AG
Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-31
Fax: +49 341 48792-39
E-Mail: ir@vita34.de

Press:

Axel Mühlhaus/Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
60318 Frankfurt

Telephone: +49 69 905505-52
Fax: +49 69 905505-77
E-Mail: vita34@edicto.de

This Interim Report was published in German and English on April 15, 2009 and is available for download on our internet site.

VITA 34 on the Internet: www.vita34.de

VITA 34 International AG

Deutscher Platz 5
04103 Leipzig

Telephone: +49 341 48792-40
Fax: +49 341 48792-39

Internet: www.vita34.de
E-Mail: ir@vita34.de

